Sahar Javanmard

Array ( [id] => 20706575 [patent_doc_number] => 20260130903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-14 [patent_title] => METHODS OF ADMINISTERING A VOLTAGE-GATED POTASSIUM CHANNEL OPENER [patent_app_type] => utility [patent_app_number] => 19/412760 [patent_app_country] => US [patent_app_date] => 2025-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17823 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19412760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20458237 [patent_doc_number] => 20260007657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-08 [patent_title] => PHARMACEUTICAL COMPOSITION FOR KERATOSIS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/323422 [patent_app_country] => US [patent_app_date] => 2025-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19323422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20406333 [patent_doc_number] => 20250375442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-11 [patent_title] => COMBINATION THERAPY WITH CLK/DYRK INHIBITORS AND BCL2 INHIBITORS TO TREAT LEUKEMIA [patent_app_type] => utility [patent_app_number] => 19/299240 [patent_app_country] => US [patent_app_date] => 2025-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19299240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20818496 [patent_doc_number] => 12673957 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-07 [patent_title] => Inhibition of glial cell activation [patent_app_type] => utility [patent_app_number] => 19/295468 [patent_app_country] => US [patent_app_date] => 2025-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 15 [patent_no_of_words] => 11800 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 319 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19295468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20459353 [patent_doc_number] => 20260008776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-08 [patent_title] => CRYSTAL FORM AND SALT FORM OF FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE [patent_app_type] => utility [patent_app_number] => 19/257024 [patent_app_country] => US [patent_app_date] => 2025-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19257024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20633418 [patent_doc_number] => 12594281 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-07 [patent_title] => Pharmaceutical dosage forms and methods of use [patent_app_type] => utility [patent_app_number] => 19/210898 [patent_app_country] => US [patent_app_date] => 2025-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 10141 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19210898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20127898 [patent_doc_number] => 12370198 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Pharmaceutical compositions and methods for treating psychiatric disorders [patent_app_type] => utility [patent_app_number] => 19/018731 [patent_app_country] => US [patent_app_date] => 2025-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 0 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19018731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19875784 [patent_doc_number] => 20250108041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => USE OF CHIDAMIDE IN PREPARING DRUG FOR TREATING RENAL FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/964259 [patent_app_country] => US [patent_app_date] => 2024-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18964259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743944 [patent_doc_number] => 20250032509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => Testosterone Ester Triglyceride Formulations [patent_app_type] => utility [patent_app_number] => 18/896012 [patent_app_country] => US [patent_app_date] => 2024-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22945 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18896012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20534441 [patent_doc_number] => 12551492 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-17 [patent_title] => Enthesis healing [patent_app_type] => utility [patent_app_number] => 18/793674 [patent_app_country] => US [patent_app_date] => 2024-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 2463 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18793674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19860698 [patent_doc_number] => 20250099484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => METHOD OF USING ILOPROST FOR TREATING FROSTBITE [patent_app_type] => utility [patent_app_number] => 18/776438 [patent_app_country] => US [patent_app_date] => 2024-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18776438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20098865 [patent_doc_number] => 20250228801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-17 [patent_title] => USE OF Galectin-1 INHIBITOR IN PREPARATION OF DRUG FOR TREATING PULMONARY FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/741100 [patent_app_country] => US [patent_app_date] => 2024-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18741100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127170 [patent_doc_number] => 20240132523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/516438 [patent_app_country] => US [patent_app_date] => 2023-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18516438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018876 [patent_doc_number] => 20240075047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => aPKC INHIBITORS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE OR DISORDER [patent_app_type] => utility [patent_app_number] => 18/506916 [patent_app_country] => US [patent_app_date] => 2023-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18506916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142135 [patent_doc_number] => 20240140959 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS [patent_app_type] => utility [patent_app_number] => 18/497296 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448821 [patent_doc_number] => 20240308951 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES [patent_app_type] => utility [patent_app_number] => 18/379142 [patent_app_country] => US [patent_app_date] => 2023-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37449 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18379142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417233 [patent_doc_number] => 20240293356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => Cannabinoid Formulations [patent_app_type] => utility [patent_app_number] => 18/484881 [patent_app_country] => US [patent_app_date] => 2023-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18484881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922866 [patent_doc_number] => 20240025870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 18/375745 [patent_app_country] => US [patent_app_date] => 2023-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10401 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18375745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297467 [patent_doc_number] => 20240226032 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID [patent_app_type] => utility [patent_app_number] => 18/477467 [patent_app_country] => US [patent_app_date] => 2023-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297467 [patent_doc_number] => 20240226032 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID [patent_app_type] => utility [patent_app_number] => 18/477467 [patent_app_country] => US [patent_app_date] => 2023-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477467 [rel_patent_id] =>[rel_patent_doc_number] =>)